Active Ingredient(s): Nilutamide
FDA Approved: * September 19, 1996
Pharm Company: * SANOFI AVENTIS US
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Nilandron Overview

Nilutamide, sold under the brand names Nilandron and Anandron, is a nonsteroidal antiandrogen (NSAA) which is used in the treatment of prostate cancer.[7][8][9][10][11][12] It has also been studied as a component of feminizing hormone therapy for transgender women and to treat acne and seborrhea in women.[13][14][15][16] It is taken by...

Read more Nilandron Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Nilandron Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Tablet: 150mg, 50mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Nilandron: (3 results)

Sorted by National Drug Code
  • 0088-1111 Nilandron 150 mg Oral Tablet by Sanofi-aventis U.S. LLC
  • 24987-111 Nilandron 150 mg Oral Tablet by Covis Pharmaceuticals, Inc.
  • 59212-111 Nilandron 150 mg Oral Tablet by Concordia Pharmaceuticals Inc.

Other drugs which contain Nilutamide or a similar ingredient: (1 result)